Partnership to Fight Chronic Disease

#AntimicrobialResistance is an increasing global public health threat, especially for people living with chronic disease. Watch for more specifics on #AMR and #cancer: https://lnkd.in/e-QgcFTx #USAAW24 #WAAW2024 #Fight4Health

November 17 was #CervicalCancer Elimination Day of Action! Hear from Colorado Majority Leader Monica Duran & American Cancer Society about the life-saving importance of screenings. Early detection is key! Learn more: https://lnkd.in/e-yKMzss #Fight4Health #EndCervicalCancer

POLL: 89% of Americans think that @MedicareGov should immediately cover the cost of new #Alzheimers medicines. (Right now, Alzheimer’s meds are covered under a clunky set of @CMSgov requirements known as “coverage with evidence development.”) Read more: https://lnkd.in/evJ2BKGZ

Join us tomorrow 11/17 in Chicago at American Heart Association's #AHA24 for "At What Cost: The Cardiovascular Edition" where PFCD's Ken Thorpe talks with StopAfib.org's Mellanie True Hills, CSP, Partnership To Advance Cardiovascular Health's Joe Dolan, Dr. Alison Bailey & PhRMA's Michael Ybarra, MD. RSVP - https://lnkd.in/e8Zr4ipd

Recently @Aging_Research @pfcd & @UsAgainstAlz released new polling data showing a bipartisan majority of voters believe @MedicareGov beneficiaries should have access to @US_FDA-approved #Alzheimers medications the same way they do for all other diseases. https://lnkd.in/eCiJ6D2J

November is #AlzheimersAwarenessMonth. Did you know about the coverage and access barriers to FDA-approved treatments for #Alzheimers? Learn more: https://lnkd.in/gPtzQ8EW

Be sure to catch the next segment in our Inflation Reduction Act (IRA) webinar series, the IRA Impact on Innovation in Drug Development on November 12. Join us as we bring together perspectives from patient advocacy groups and biotech professionals to discuss the emerging concerns and explore actionable strategies to mitigate potential access limitations for patients. Panelists include: - Catherine Sabatos-Peyton, CEO, Larkspur Biosciences - Candace DeMatteis, Policy Director, Partnership to Fight Chronic Disease - Moderator: Martin Strebl-Bantillo, PhD, Principal, Strategy Consulting, Lumanity Register at https://buff.ly/4f5awjS #InflationReductionAct #IRA #DrugDevelopment #PatientAdvocacy #Biotech #PatientAccess #HealthCarePolicy

The Black maternal health crisis is an urgent public health issue, and equitable data collection is key to understanding and addressing the disparities. ?? Join Us for an insightful event on October 18th at 12PM ET/9AM PT for an Important Live Discussion, "Centering Data Equity in the Black Maternal Health Crisis" ??, where we will explore how data equity can drive meaningful solutions and improve maternal health outcomes not limited to Black women but also women of color and birthing persons. Register today to be a part of this critical and timely conversation! bit.ly/NMQF1018

“People stand for fairness in #Medicare coverage and reject Medicare’s policies that erect barriers to treatment,” said?Ken Thorpe, Chair of the Partnership to Fight Chronic Disease. “The American people recognize the importance of quality time for patients and families navigating #Alzheimers and support policymakers who act to ensure access.” PRESS RELEASE: https://bit.ly/3YiFBdR

JOIN US TOMORROW Thursday, October 10 Noon - 12:45 PM ET for: A new Lake Research Partners and Public Opinion Strategies Survey release: “What Do Likely Voters Think of Medicare’s Coverage Policy for FDA-approved Early Alzheimer’s Treatments?” REGISTER for the live Zoom event here: https://lnkd.in/eRjX5ks4 The poll was commissioned by the Alliance for Aging Research, the Partnership to Fight Chronic Disease, and UsAgainstAlzheimer's. BACKGROUND: Since April 2022, the Medicare program (run by the Centers for Medicare & Medicaid Services) has required "coverage with evidence development" (CED) for all FDA-approved early Alzheimer’s therapies. Under a CED, Medicare indiscriminately mandates that beneficiaries enroll in clinical studies for coverage of selected treatments, or else coverage will be denied. The program also imposes strict eligibility criteria on the health professionals and hospitals that can qualify to collect data and run the studies. The net effect is only a small fraction of Medicare beneficiaries have gotten access to the two current early Alzheimer’s treatments available, #Leqembi and #Kisunla. NO other FDA-approved drugs for on-label use in other diseases have been subject to CED. Other public and private payers have followed Medicare’s lead, including TriCare and Cigna Healthcare. Several other private payers use complex guidelines to deter utilization. Where are likely voters on the issue today? Tune in tomorrow to find out! #TalkAboutAgeism #StopRationingCare #StayTuned